Table 4.

Results from the Intervention Testing Program. With the exception of rapamycin, interventions preferentially increased longevity in male mice.

Compound	Amount in Food	Age at treatment initiation	Females (Median; at 90% mortality)	Males (Median; at 90% mortality)	Source
Aspirin	20 ppm	4 months	0; 0	Increased 8%; 0	(Strong et al., 2008a)
NFP	200 ppm	4 months	0; 0	0; 0	(Strong et al., 2008a)
NDGA	2500 ppm	9 months	0; 0	Increased 12%; 0	(Strong et al., 2008a)
4-OH-PBN	315 ppm	4 months	0; 0	0; 0	(Strong et al., 2008a)
CAPE	30 ppm	4 months	0; 0	0; 0	(Harrison et al., 2009)
CAPE	300 ppm	4 months	0; 0	0; 0	(Harrison et al., 2009)
Enalapril Maleate	120 ppm	4 months	0; 0	0; 0	(Harrison et al., 2009)
Rapamycin	14 ppm	20 months	Increased 13(38)%*	Increased 9(28)%*	(Harrison et al., 2009)
Rapamycin	14 ppm	9 months	Increased18%; Increased 13%;	Increased 10%; Increased 16%;	(Miller et al., 2011)
Simvastatin	12 ppm	10 months	0; 0	0; 0	(Miller et al., 2011)
Simvastatin	120 ppm	10 months	0; 0	0; 0	(Miller et al., 2011)
Resveratrol	300 ppm	12 months	0; 0	0; 0	(Miller et al., 2011)
Resveratrol	1200 ppm	12 months	0; 0	0; 0	(Miller et al., 2011)
Resveratrol	300 ppm	4 months	0; 0	0; 0	(Strong et al., 2013)
Oxaloacetic acid	2200 ppm	4 months	0; 0	0; 0	(Strong et al., 2013)
Green tea extract	2000 ppm	4 months	0; 0	0; 0	(Strong et al., 2013)
Curcumin	2000 ppm	4 months	0; 0	0; 0	(Strong et al., 2013)
Medium chain triglyceride oil	60000 ppm	4 months	0; 0	0; 0	(Strong et al., 2013)
17α-Estradiol	4.8 ppm	10 months	0; 0	Increased 12%; 0	(Harrison et al., 2014)
Methylene Blue	28 ppm	4 months	0; 0	0; 0	(Harrison et al., 2014)
Acarbose	1000 ppm	4 months	Increased 5%; Increased 9%	Increased 22%; Increased 11%	(Harrison et al., 2014)
Rapamycin_LoP hase II	4.7 ppm	9 months	Increased 16%; Increased 5%	3%; 0	(Miller et al., 2014)
Rapamycin_Mid Phase II	14 ppm	9 months	Increased 21% Increased 11%	Increased 13%; Increased 8%	(Miller et al., 2014)
Rapamycin_HiP hase II	42 ppm	9 months	Increased 26%; Increased 11%	Increased 23%; Increased 8%	(Miller et al., 2014)
NDGA Lo_Phase II	800 ppm	6 months	--**	Increased 8% (median)**	(Harrison et al., 2014)
NDGA Med_Phase II	2500 ppm	6 months	--**	Increased 10% (median)**	(Harrison et al., 2014)
NDGA Hi_Phase II	5000 ppm	6 months	0; --**	Increased 9% (median)**	(Harrison et al., 2014)